01
Selected tissue-agnostic indication
In 2020, the FDA granted accelerated approval for pembrolizumab in certain unresectable or metastatic solid tumors progressing after prior treatment with no satisfactory alternative, for TMB-high disease (≥10 mut/Mb using an FDA-approved test). This cutoff is not automatically transferable to every tumor or assay.
Assay and specimen: Broad, analytically and clinically validated NGS, documenting mut/Mb and the exact calculation method.
Clinical interpretation: The 10 mut/Mb threshold belongs to a specific indication; values from small panels or different algorithms may not be comparable.
02
Molecular tumor board decision support
Consider TMB together with tumor type, MSI/MMR, PD-L1, prior treatments, performance status, and other molecular features in multidisciplinary review.
Assay and specimen: Use sufficient-quality tumor DNA and document effective panel coverage.
Clinical interpretation: TMB-H has variable predictive value across cancers with different baseline immunotherapy responsiveness.
03
Understanding elevated TMB
Mismatch repair defects and mutagenic exposures can produce elevated TMB, but these biomarkers measure distinct biological features.
Assay and specimen: Obtain validated MSI/MMR testing separately when indicated.
Clinical interpretation: CAP/ASCO specifically advise against using TMB as a proxy for dMMR.